l-Malic Acid Potentiates Bifidobacterium breve Bb18 Tolerance and Synergistically Ameliorates Colitis via Gut Microbiota-Metabolite Modulation.

0.4% l-malic acid optimally enhanced Bb18 tolerance to glycodeoxycholic acid (GDCA) by 52.3% in vitro.

• The concentration of 0.4% l-MA was identified as the optimal dose for enhancing bile tolerance.
• The enhancement was specifically measured against glycodeoxycholic acid (GDCA).
• Mechanisms included preserving membrane integrity, boosting energy metabolism, and upregulating bile salt efflux genes.
• The authors describe this as 'promoting a multidimensional cellular adaptive response.'

The combination of Bb18 and l-MA synergistically alleviated colon length shortening by 20.1% in DSS-induced colitis mice.

• The study used a DSS-induced colitis mouse model.
• Colon length shortening, a hallmark of colitis severity, was reduced by 20.1% with the combination treatment.
• The combination also reduced inflammation and restored gut barrier integrity.
• The effect was described as synergistic, implying greater efficacy than either component alone.

l-MA potentiated Bb18 colonization under inflammatory stress by 217.6%.

• This colonization enhancement was observed in the context of inflammatory stress in vivo.
• The 217.6% increase indicates that l-MA substantially improved the ability of Bb18 to establish in the gut during colitis.
• Improved colonization is described as a critical mechanism underlying the synergistic therapeutic effect.
• This finding supports l-MA as a protective synbiotic partner for probiotic delivery under disease conditions.

The Bb18 and l-MA combination simultaneously modulated gut microbiota composition and increased barrier-protective metabolites linked to inflammation resolution.

• The combination treatment affected both the gut microbial community structure and metabolite profiles.
• Increased barrier-protective metabolites were mechanistically linked to inflammation resolution.
• This dual modulation of microbiota and metabolites represents a proposed mechanism of action for the synergistic effect.
• The findings support a gut microbiota-metabolite modulation pathway as central to the therapeutic efficacy.

l-MA functions as a protective synbiotic partner for Bb18, offering a novel combinatorial strategy for probiotic-enhanced colitis management.

• The study establishes l-MA in the role of a synbiotic component rather than just a prebiotics or food additive.
• The protective effects were demonstrated both in vitro (bile tolerance) and in vivo (colonization and anti-inflammatory effects).
• The combination strategy addresses the challenge of probiotic survival and colonization under inflammatory conditions.
• Authors propose this as 'a novel combinatorial strategy for probiotic-enhanced colitis management.'